Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
Authors
Keywords
-
Journal
CANCER AND METASTASIS REVIEWS
Volume 31, Issue S1, Pages 11-17
Publisher
Springer Nature
Online
2012-06-06
DOI
10.1007/s10555-012-9354-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
- (2011) Camillo Porta et al. BJU INTERNATIONAL
- Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
- (2011) V Grünwald et al. BRITISH JOURNAL OF CANCER
- ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
- (2011) Jean-Jacques Patard et al. EUROPEAN UROLOGY
- Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
- (2011) James Larkin et al. Expert Review of Anticancer Therapy
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer
- (2011) Michael Grundbichler et al. ONCOLOGY
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) B. Escudier et al. ANNALS OF ONCOLOGY
- Targeting mTOR in renal cell carcinoma
- (2010) Gary R. Hudes CANCER
- Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
- (2010) Jorge A. Garcia et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- EORTC-GU group expert opinion on metastatic renal cell cancer
- (2009) Theo M. de Reijke et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
- (2009) M.P. Sablin et al. JOURNAL OF UROLOGY
- Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
- (2009) Holger Gerullis et al. MEDICAL ONCOLOGY
- Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib
- (2009) Kaja Zimmermann et al. ONCOLOGY
- Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
- (2008) Arkadiusz Z. Dudek et al. CANCER
- Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors
- (2008) N. T. Fernando et al. CLINICAL CANCER RESEARCH
- Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
- (2008) Christian Eichelberg et al. EUROPEAN UROLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started